30.84

6.64% 1.92

Pre-market: 31.45 0.61 +1.98%

Avidity Biosciences Inc (RNA)

Overview News Price History Option Chain Financials Discussions Forecast

Avidity Biosciences Inc stock is traded at $30.84, with a volume of 1.38M. It is up +6.64% in the last 24 hours and down -3.08% over the past month. Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product, AOC 1001, is designed to treat a rare monogenic muscle disease.

Previous Close:

$28.92

Open:

$28.59

24h Volume:

1.38M

Relative Volume:

1.20

Market Cap:

$3.68B

Revenue:

$10.12M

Net Income/Loss:

$-280.49M

P/E Ratio:

-10.67

EPS:

-2.89

Net Cash Flow:

$-188.51M

1W Performance:

+14.01%

1M Performance:

-3.08%

6M Performance:

-31.65%

1Y Performance:

+203.54%

1-Day Range:

$28.59

$31.30

1-Week Range:

$27.49

$31.30

52-Week Range:

$9.93

$56.00

Avidity Biosciences Inc Stock (RNA) Company Profile

Name

Avidity Biosciences Inc

Sector

Healthcare (1176)

Industry

Biotechnology (685)

Phone

858-401-7900

Address

10578 SCIENCE CENTER DRIVE, SAN DIEGO, CA

Employee

253

Twitter

Next Earnings Date

2024-12-07

Latest SEC Filings

RNA's Discussions on Twitter

Compare RNA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RNA Avidity Biosciences Inc	30.84	3.68B	10.12M	-280.49M	-188.51M	-2.89
VRTX Vertex Pharmaceuticals Inc	427.89	110.19B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	687.80	75.58B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	647.39	38.71B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	264.99	34.18B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	117.25	28.11B	3.30B	-501.07M	1.03B	-2.1146

Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-20-24	Initiated	H.C. Wainwright	Buy
Nov-26-24	Initiated	RBC Capital Mkts	Outperform
Sep-24-24	Initiated	Goldman	Buy
Aug-28-24	Initiated	Barclays	Overweight
May-03-24	Initiated	BofA Securities	Buy
Mar-14-24	Initiated	Cantor Fitzgerald	Overweight
May-22-23	Upgrade	Evercore ISI	In-line → Outperform
Mar-31-23	Downgrade	Evercore ISI	Outperform → In-line
Jul-20-22	Initiated	Chardan Capital Markets	Buy
Jul-12-22	Initiated	Raymond James	Strong Buy
Sep-07-21	Initiated	Evercore ISI	Outperform
Jun-17-21	Initiated	Needham	Buy
Apr-26-21	Resumed	Credit Suisse	Outperform
Jul-07-20	Initiated	Cowen	Outperform
Jul-07-20	Initiated	Credit Suisse	Outperform
Jul-07-20	Initiated	SVB Leerink	Outperform
Jul-07-20	Initiated	Wells Fargo	Overweight

View All

Avidity Biosciences Inc Stock (RNA) Latest News

Jan 21, 2025

Royal Bank of Canada Reiterates Outperform Rating for Avidity Biosciences (NASDAQ:RNA) - MarketBeat

Jan 21, 2025

Jan 20, 2025

Exciting News from Avidity Biosciences! New Opportunities Await! - Qhubo

Jan 20, 2025

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StreetInsider.com

Jan 20, 2025

Avidity Biosciences Awards New Employee Stock Options and RSUs Worth $304K - StockTitan

Jan 20, 2025

Jan 17, 2025

12 Biotech Stocks with the Biggest Upside Potential - Insider Monkey

Jan 17, 2025